

RESEARCH ARTICLE

[View Article Online](#)
[View Journal](#)Cite this: DOI: 10.1039/
d5md00888cOxadiargyl analogs as potent inhibitors of
Toxoplasma gondii protoporphyrinogen oxidaseSamuel Kwain,^{†ac} Vikky Awasthi,^{†c} Rajib Islam,^{ac} Shivani Kore,^{bc} Emma Polaski,^{bc}
Kerrick C. Rees,^{id a} Zhicheng Dou^{*bc} and Daniel C. Whitehead^{id *ac}

Toxoplasma gondii infects approximately one-third of the human population, posing a severe and potentially fatal risk to individuals with compromised immune systems. Our previous studies demonstrated that modifying the arene in the herbicidal protoporphyrinogen oxidase (PPO) inhibitor, oxadiazon, yields analogs that potently inhibit *T. gondii* PPO, a key enzyme in the heme biosynthesis pathway. In this study, we further investigated the structure–activity relationship of oxadiazon analogs by introducing aliphatic chains with varying functionalities, resulting in 23 new derivatives. Some of these compounds exhibited significant intracellular inhibition of wild-type *T. gondii*, with IC₅₀ values ranging from 2 to 3 μM. Biochemical analysis confirmed that their mode of action is mediated by potent PPO inhibition, which further blocked heme production and damaged mitochondrial health status in the parasites. These findings enhance our understanding of oxadiazon's structural optimization and highlight its derivatives as promising early-stage candidates for developing effective therapies against toxoplasmosis in humans and other animals.

Received 3rd October 2025,
Accepted 31st October 2025

DOI: 10.1039/d5md00888c

rsc.li/medchem

Toxoplasma gondii, an obligate intracellular protozoan belonging to the Apicomplexa phylum, is among the most widespread parasitic organisms, infecting approximately one-third of the global human population as well as a diverse range of other warm-blooded animals.^{1–4} While acute infections are generally asymptomatic in immunocompetent individuals, they can cause severe complications in immunocompromised individuals, pregnant women, and patients undergoing chemotherapy or organ transplants. In such cases, the infection may lead to encephalitis or neurological damage, which can be life-threatening.^{4–12} Current treatment options, such as pyrimethamine and sulfadiazine, are hindered by significant side effects and limited efficacy, particularly against chronic and congenital toxoplasmosis. This highlights the urgent need for novel therapeutic strategies.¹³ One promising avenue for drug development lies in targeting the parasite's unique heme biosynthesis pathway.^{14–16} *T. gondii* synthesizes heme – an essential molecule for numerous cellular functions – via a plant-like pathway that is distinct from the pathways used by

mammals.^{16,17} This divergence presents an attractive therapeutic target, as heme biosynthesis plays a critical role in the parasite's intracellular growth and acute virulence.¹⁶ Studies have demonstrated that heme-deficient parasites exhibit significantly reduced virulence and are effectively eliminated by the host's innate immune system.¹⁶ These findings strongly suggest that disrupting heme biosynthesis could offer an effective strategy for combating *T. gondii* infections.

One of the key enzymes in the heme biosynthesis pathway is protoporphyrinogen oxidase (PPO), which in *T. gondii* shows a closer phylogenetic relationship to plant PPOs than to those in mammals.¹⁶ PPO is a well-established target in herbicide development, where inhibitors cause the accumulation of toxic intermediates that destroy plant cell membranes.¹⁸ This similarity suggests that herbicidal PPO inhibitors, which have been effectively used for weed control with high specificity and low toxicity, could serve as starting molecular scaffolds for the development of new antiparasitic compounds.

Indeed, initial work from our group identified oxadiazon (**1**) and its propargyl homolog oxadiargyl (**2**) as moderately effective against WT *T. gondii* (Fig. 1).¹⁶ Building on this study, we explored the structure–activity relationship of the homolog, oxadiargyl, by appending an aryl ring of varying functionality via a straightforward “click” chemistry approach. Five out of the 18 oxadiargyl analogs prepared showed significantly improved potency, achieving IC₅₀ values

^a Department of Chemistry, Clemson University, Clemson, SC 29634, USA.
E-mail: dwhiteh@clemson.edu

^b Department of Biological Sciences, Clemson University, Clemson, SC 29634, USA.
E-mail: zdou@clemson.edu

^c Eukaryotic Pathogens Innovation Center, Clemson University, Clemson, SC 29634, USA

[†] Both authors made equal contributions to this work.






Fig. 1 Herbicide PPO inhibitor oxadiazon (1) and derivatives (2–7) exhibit potent growth inhibition against *Toxoplasma gondii*.

between 1.0–1.9 μM against *T. gondii* (Fig. 1).¹⁹ We demonstrated that the observed inhibitory activity of these compounds against wild-type *T. gondii* resulted primarily from PPO inhibition, as they were approximately 10 to 30 times less potent against a *Toxoplasma* PPO knockout mutant

carrying a luciferase reporter, *Appo::NLuc*. The inhibitory activity was restored when the strain was complemented with *Toxoplasma* PPO (*AppoPPO::NLuc*).¹⁹ Due to the promising results from the derivatization of the arene in compounds 3–7, we elected to further explore a similar “click” chemistry-based strategy to modify oxadiargyl (2) with aliphatic motifs bearing various functionality. This study broadens our understanding of the structural drivers governing potent inhibition of *Toxoplasma* PPO and may inform the future development of an effective therapy against toxoplasmosis in humans and other animals by targeting heme biosynthesis in the parasite.

In this study, we synthesized a library of 23 oxadiazon derivatives (11a–11w, Fig. 2) containing a triazole moiety bearing aliphatic chains functionalized with diverse groups, including hydroxyl, halogen, nitrile, α-olefin, epoxide, pivalate, sulfonate, phosphonate, amino alcohol, and halohydrin. The synthesis began with the preparation of functionalized aliphatic azide intermediates, which were obtained by reacting alkyl bromides with sodium azide in DMF. In some cases, subsequent functional group interconversions afforded the desired azides in good to




Fig. 2 Triazole-oxadiargyl library evaluated against WT *T. gondii*.¹ Isolated yields.² % growth inhibition of WT *T. gondii* at 5 μM (mean ± STD for three biological replicates).³ Structures highlighted in grey background were the most potent, and IC₅₀ values were solved (mean ± STD for three biological replicates, two technical replicates each).



excellent yields (S9a–f and S10g–w; see SI for details). These azides were then subjected to copper-catalyzed Huisgen 1,3-dipolar cycloaddition with commercially available oxadiargyl (**2**), resulting in the target oxadiazon derivatives in moderate to excellent yields (**11a–w**; see SI for details). Notably, the iso-pentyl (**11a**) and heptyl (**11b**) derivatives were isolated in yields of 90% and 95%, respectively. Similarly, derivatives bearing α -olefin (**11c**), butylbenzene (**11d**), butoxymethylbenzene (**11e**), and hydroxyl (**11f**) groups were obtained in 90–96% yield. The sulfonate (**11g**) and pivalate (**11h**) derivatives were isolated in 80% and 90% yield, respectively, while halogenated derivatives (**11i**, 90%; **11j**, 90%) as well as nitrile (**11k**, 98%) and epoxide (**11l**, 92%) derivatives were successfully synthesized. Additional analogs included halohydrin derivatives (**11m**, 78%; **11n**, 82%) and a series of amino alcohol derivatives (**11o–r**) isolated in 86–92% yield. Finally, phosphonate derivatives (**11s–u**) were obtained in 85–90% yield, while the corresponding phosphonic acid derivatives **11v** and **11w** were isolated in 68% and 74% yields, respectively.

Oxadiazon derivatives **11a–w** were assessed for their ability to inhibit the intracellular growth of wild-type *T. gondii* expressing a luciferase reporter at 5 μ M concentration, using our previously developed assay.^{16,17,19} The average percent inhibition over three biological replicates was calculated, and six compounds exhibited $\geq 95\%$ growth inhibition (*i.e.* compounds **11b**, **11i**, **11k**, **11m**, **11q**, and **11r**). IC_{50} values were calculated for the three most potent analogs, **11b** ($2.25 \pm 0.19 \mu$ M), **11i** ($3.03 \pm 0.61 \mu$ M), and **11k** ($2.12 \pm 0.61 \mu$ M) (Fig. 2, shaded boxes). We next elected to move forward with additional evaluations of **11k** owing to its strong potency and more favorable solubility profile.

First, the IC_{50} of **11k** against WT *T. gondii* was compared to PPO-knockout and complemented strains bearing the luciferase reporter (Table 1).^{16,19} Consistent with our previous findings,¹⁹ oxadiazon analog **11k** primarily inhibits intracellular growth of *T. gondii* by targeting PPO, thereby disrupting heme biosynthesis. Compound **11k** was approximately 9.5 times less potent against the knockout mutant, reinforcing that PPO inhibition is its primary mechanism of action (Table 1, column 3). Furthermore, its potency was restored against a strain complemented with *Toxoplasma* PPO (*AppoPPO::NLuc*), further supporting PPO disruption as the primary mode of inhibition (Table 1, column 4). Additionally, **11k** was evaluated for cytotoxicity against human foreskin fibroblast (HFF) cells using the alamarBlue viability assay and only exhibited slight cytotoxicity at 100 μ M.

Our previous work demonstrated that deletion of TgPPO disrupted heme biosynthesis by $\sim 50\%$ and impaired the parasite lytic cycle.¹⁶ Based on this, we hypothesized that **11k** treatment would inhibit parasite growth by targeting TgPPO and reducing heme production. To test this, parasites were cultured in the presence of **11k** at $1 \times IC_{50}$ (2.1 μ M) or $3 \times IC_{50}$ (6.3 μ M), and proliferation was quantified using a luciferase-based assay reported before.¹⁶ After 96 h of treatment, parasite growth was reduced by 57% and 90% at $1 \times IC_{50}$ and $3 \times IC_{50}$, respectively (Fig. 3A), relative to the vehicle control (*i.e.* DMSO-treated parasites). We next assessed whether the treatment of **11k** decreases heme abundance in the parasites. Parasites were cultured with **11k** at $1 \times IC_{50}$ and $3 \times IC_{50}$ for 4 days, with fresh inhibitor added daily, and intracellular heme levels were quantified using a fluorescence-based assay.²⁰ Heme content was decreased by 22% and 48% at $1 \times IC_{50}$ and $3 \times IC_{50}$, respectively (Fig. 3B) compared to the DMSO-treated control, confirming that **11k** was able to penetrate the parasite's membrane and perturbed the heme biosynthetic pathway in the parasites.

Since **11k** treatment at 6.3 μ M reduced heme abundance by $\sim 50\%$, similar to the inhibition observed in the TgPPO knockout,¹⁶ we next investigated its impact on mitochondrial physiology at $3 \times IC_{50}$. First, mitochondrial membrane potential was evaluated using the JC-1 assay, in which healthy mitochondria promote red J-aggregate formation, whereas depolarized mitochondria emit green fluorescence. Treatment with **11k** decreased the red/green ratio by 23% compared to DMSO-treated parasites (Fig. 3C), indicating that mitochondrial membrane potentials are reduced due to lack of heme production, which further impairs the function of the mitochondrion by reducing hemoprotein translocation. To further characterize mitochondrial function, we performed a modified mitochondrial stress test using Seahorse analysis (Fig. 3D). Since *T. gondii* lacks ETC complex I and possesses a unique complex III,^{21,22} atovaquone (ATQ) was used to fully block respiration. Parasites treated with **11k** showed a 58% reduction in basal respiration, while maximal and spare respiration rates were decreased by 72% and 92%, respectively (Fig. 3D). These data suggest that reduced heme production in the parasites impaired electron transport chain (ETC) activity, likely through decreased availability of hemoproteins such as cytochromes.

In conclusion, we have developed a library of oxadiazon derivatives bearing functionalized alkyl groups appended to the scaffold by means of a straightforward click chemistry approach. Six of the compounds exhibited $\geq 95\%$ intracellular growth inhibition of WT *T. gondii* at 5 μ M concentration. The three most potent compounds, **11b**, **11i**, and **11k**, exhibited

Table 1 Evaluation of selected oxadiazon derivatives against wild-type, knockout, and complemented strains of *Toxoplasma gondii*

Compound	WT::NLuc ^a (μ M)	Appo::NLuc (μ M)	AppoPPO::NLuc (μ M)
11k	2.12 ± 0.61	20.24 ± 11.3	1.21 ± 0.63

^a IC_{50} values for intracellular growth inhibition (mean \pm STD for three biological replicates, two technical replicates each).






Fig. 3 Compound **11k** treatment significantly inhibited parasite growth, heme production, and mitochondrial function in *Toxoplasma gondii*. (A) Parasite growth was severely reduced at $1 \times IC_{50}$ and $3 \times IC_{50}$ concentrations of **11k**, as determined by a luciferase-based growth assay. (B) Heme levels were decreased in *Toxoplasma* parasites following **11k** treatment, measured by a fluorescence-based heme assay. (C) Mitochondrial membrane potential was reduced in **11k**-treated parasites. Parasites treated with CCCP served as a positive control. (D) Schematic representation of the modified Seahorse mitochondrial stress test, indicating the bioenergetic parameters measured (i.e. basal, maximal, and spare mitochondrial OCRs). A representative stress assay is shown, and average values from four biological replicates were plotted for statistical comparison. Statistical significance in panels (A to C) was determined by one-way ANOVA, and bioenergetic results in panel (D) were analyzed using paired *t*-tests. n.s., not significant; *, $p < 0.05$; **, $p < 0.01$; ****, $p < 0.0001$. Abbreviations: CCCP, carbonyl cyanide *m*-chlorophenyl hydrazine; FCCP, carbonyl cyanide-*p*-trifluoromethoxyphenylhydrazine; ATV, atovaquone.

IC_{50} values ranging between 2.25 and 3.03 μM . Evaluation of **11k** against PPO-knockout and complemented strains of *T. gondii* confirmed that PPO disruption is the main pathway for responsible for growth inhibition. Our biological findings demonstrate that the oxadiazon derivative **11k** inhibits TgPPO, disrupts heme biosynthesis, and severely compromises mitochondrial activity in *Toxoplasma* parasites.

Methods

General methods

Chemistry. All reagents were purchased from commercial sources and used without purification unless otherwise noted. All non-aqueous reactions were performed under an inert atmosphere of nitrogen in flame-dried glassware containing a stir bar. Acetonitrile (ACN), tetrahydrofuran (THF), dichloromethane (DCM), methanol (MeOH), dimethylformamide (DMF) and pyridine (py) were obtained from commercial sources and dried following standard distillation procedures. All other solvents were obtained from commercial sources and used without drying unless otherwise noted. All water and aqueous solutions were made using deionized (DI) water. Flash column chromatography was carried out using ZEOCHEM silica gel (40–63 μm).

Analytical and preparative thin-layer chromatography (TLC) were performed on Sorbtech silica gel TLC plates. 1H and ^{13}C NMR including 2D NMR spectra were obtained using Bruker avance 300 and 500 MHz spectrometers. Chemical shifts are reported in parts per million (ppm). Spectra are referenced to residual solvent peaks. The following abbreviations were used to designate multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, sx = sextet, sep = septet, m = multiplet, br = broad. Infrared spectroscopy data were collected using an IR Affinity-1S instrument (with MIRacle 10 single reflection ATR accessory), and peaks are described as strong (s), moderate (m), and weak (w). All known compounds were characterized by 1H and ^{13}C NMR and are in complete agreement with samples reported elsewhere. All new compounds were characterized by 1H , ^{13}C and 2D NMR, ATR-FTIR, HRMS, and melting point (where appropriate). HRMS data were collected using an instrument equipped with electrospray ionization in positive mode (ESI⁺) and a time-of-flight (TOF) detector.

Mammalian cell and parasite culture

Toxoplasma gondii parasites were passaged in human foreskin fibroblasts (HFFs, ATCC, SCRC-1041), which were grown in



Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% cosmic calf serum (D10 medium), 10 mM HEPES, 4 mM glutamine, 100 U penicillin/streptomycin at 37 °C with 5% CO₂.

Evaluation of inhibition potency of oxidiazol-triazole derivatives using the bioluminescence-based growth assay

The initial screening of synthesized oxadiazon derivatives was performed at 5 μM. Freshly lysed parasites were harvested by membrane filtration, as previously described.¹⁷ A total of 1500 RHΔ*ku80Δhxc::NLuc* parasites (referred to as WT::NLuc hereafter) were inoculated into each well of 96-well white plates. Parasites were allowed to invade host cells for 4 h, after which non-invaded parasites were washed away, and the medium was replaced with fresh D10 supplemented with 5 μM oxadiazon derivatives. Wells containing D10 medium with DMSO served as vehicle controls for normalization of parasite growth across treatments. Parasites were allowed to grow for 96 h, and bioluminescence was determined as previously described.¹⁷ Growth inhibition was calculated using the following equation: ((mean readings of bioluminescence from the wells incubated with DMSO – mean readings of bioluminescence from the wells incubated with oxadiazon derivatives)/mean reading of bioluminescence from the wells incubated with DMSO) × 100%. Compounds were then ranked from highest to lowest inhibition.

The top three derivatives were further evaluated to determine their half-maximal inhibitory concentrations (IC₅₀). Following the same procedures, 1500 WT::NLuc, 1500 Δ*ppoPPO::NLuc*, or 7500 Δ*ppo::NLuc* parasites were inoculated into 96-well plates. The maximum concentration of each compound was 100 μM, followed by three-fold serial dilutions across 10 concentrations. Wells containing DMSO served as vehicle controls. Normalized bioluminescence readings were plotted in Prism version 10 and fitted using the [inhibitor] vs. normalized response function. All assays were performed in three independent biological replicates, each with two technical replicates. Calculated IC₅₀ values were averaged, and the standard deviations were reported.

Toxicity quantification of oxidiazol triazole derivatives in HFFs using the alamarBlue assay

Human foreskin fibroblasts (HFFs) were seeded into 96-well clear plates and grown to confluent monolayers. Compound **11k** was prepared in D10 medium at an initial concentration of 100 μM and subsequently serially diluted in 3-fold increments to obtain 11 final concentrations, and the cells were incubated for 96 h at 37 °C with 5% CO₂. Following treatment, the medium was replaced with D10 containing 0.004% (m/v) resazurin and incubated for 4 h under the same conditions. Absorbance was then measured at 570 and 600 nm using a BioTek H1 hybrid plate reader. Cell viability was calculated according to previously reported methods.¹⁹

Heme quantification in *Toxoplasma* parasites

Toxoplasma parasites were cultured with or without compound **11k** at concentrations corresponding to the 1× IC₅₀ or 3× IC₅₀ for 48 h prior to purification. Culture medium was replenished every 24 h with freshly supplemented compound. Parasites were harvested by syringe passage, filter purification, and resuspension in ice-cold PBS, followed by centrifugation at 1000 × *g* for 10 min at 4 °C. The pellet was washed twice with PBS, each time centrifuged at 1000 × *g* for 10 min at 4 °C. The final pellet was counted using a hemocytometer, centrifuged at 5000 × *g* for 5 min at 4 °C, resuspended in 400 μL of ice-cold PBS, and subjected to sonication.

Parasite lysates were sonicated three times using a Branson Analog Sonifier S-250A equipped with a tapered 1/8 inch microtip (output intensity = 3, duty cycle = 20%), with 30-sec intervals between pulses to prevent overheating. Heme standards were prepared in parallel to calculate heme content per parasite. For measurement, 100 μL of parasite lysate or heme standard was mixed with 900 μL of 2 M aq. oxalic acid and vortexed. One set of samples was boiled for 30 min, while the other was kept at room temperature to serve as a background control. Two hundred microliters of each oxalic acid/sample mixture were transferred in triplicate into black 96-well plates and measured using a BioTek Synergy H1 hybrid multi-mode microplate reader under the following settings: excitation = 400 nm, emission = 608 nm, optics = top, gain = 135, read speed = normal, delay = 100 msec, measurements/data point = 10, and read height = 7 mm. The assay was performed in at least three independent biological replicates for statistical comparison.

Mitochondrial membrane potential quantification

To assess the health status of drug-treated parasites, a JC-1 assay was used to quantify mitochondrial membrane potential. **11k**-treated parasites were filter-purified, centrifuged, washed, and resuspended in PBS at 5 × 10⁸ tachyzoites per mL. Parasite suspensions were incubated at 37 °C with 2 μM JC-1 dye for 15 min. Wild-type parasites treated with CCCP (carbonyl cyanide *m*-chlorophenylhydrazine) served as positive controls. Following staining, parasites were washed once with warm PBS to remove residual dye and resuspended at 5 × 10⁸ tachyzoites per mL. Aliquots of 100 μL were loaded into black 96-well plates in triplicate, and fluorescence was measured at excitation 488 nm with emission recorded at 530 nm (green) and 585 nm (red). The ratio of red (585 nm) to green (530 nm) fluorescence was reported as an indicator of mitochondrial membrane potential. The assay was performed in four independent biological replicates.

Seahorse mitochondrial stress assay

To evaluate the bioenergetic parameters of the parasite's mitochondria, we performed an Agilent Seahorse mitochondrial stress test to measure basal, maximal, and




spare mitochondrial oxygen consumption rates (mOCRs). Because *Toxoplasma* mitochondria lack ETC complex I and possess a unique complex III, rendering them insensitive to rotenone and antimycin A,²¹ atovaquone (ATQ) was used to completely inhibit mitochondrial respiration. Following the manufacturer's instructions, freshly lysed, filter-purified parasites were seeded at 2.5×10^6 tachyzoites per well on CellTak-coated 24-well Seahorse plates (Agilent). Parasites were incubated in DMEM medium (Agilent) supplemented with 10 mM glucose and 4 mM L-glutamine for basal OCR measurements. FCCP (2 μ M) and ATQ (1 μ M) were sequentially injected to induce maximal respiration and then fully block mitochondrial respiration, respectively. Oxygen consumption rates were recorded three times following each injection. Energetic parameters were calculated as previously described.²² The assay was repeated in four biological replicates.

General procedure for synthesis of oxadiargyl-triazole derivatives 11a–w


In a flame-dried 20 mL round-bottom flask equipped with a magnetic stir bar, oxadiargyl (0.2 mmol) was dissolved in a 1:1 mixture of DCM and water (2 mL). The appropriate azide (0.24 mmol) was then added, followed by anhydrous CuSO₄ (0.01 mmol) and sodium ascorbate (0.03 mmol). The reaction mixture was stirred vigorously at room temperature for 6 h. Upon completion, the mixture was dried and purified by flash chromatography on silica gel, using gradient elution from 100% hexanes to 80% hexanes/ethyl acetate. This process afforded the corresponding oxadiargyl derivative as an off-white oil or solid in 65–98% isolated yield.

Analytical data for oxadiargyl-triazole derivatives 11a–w


5-(*tert*-Butyl)-3-(2,4-dichloro-5-((1-isopentyl-1*H*-1,2,3-triazol-4-yl)methoxy)phenyl)-1,3,4-oxadiazol-2(3*H*)-one. Off-white viscous oil (90% yield); IR: (neat) ν (cm⁻¹): 2984, 1761, 1623, 1421, 1415, 1316, 1274, 1124, 1108, 1075, 926, 921, 756, 536; ¹H NMR (500 MHz, CDCl₃) δ 7.68 (s, 1H), 7.54 (s, 1H), 7.26 (s, 1H), 5.32 (s, 2H), 4.44–4.35 (m, 2H), 1.89–1.79 (m, 2H), 1.61 (s, 1H), 1.39 (s, 9H), 0.98 (d, J = 6.7 Hz, 6H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 163.6, 153.0, 152.1, 142.7, 131.4, 125.2, 123.9, 122.8, 113.8, 63.8, 48.9, 38.9, 33.0, 27.0, 25.6, 22.2; HRMS (ESI-TOF) m/z : [M + H]⁺ calcd for C₂₀H₂₆Cl₂N₅O₃ 454.1413; found 454.1415.



5-(*tert*-Butyl)-3-(2,4-dichloro-5-((1-heptyl-1*H*-1,2,3-triazol-4-yl)methoxy)phenyl)-1,3,4-oxadiazol-2(3*H*)-one. Off-white viscous oil (95% yield); IR: (neat) ν (cm⁻¹): 3045, 1778, 1643, 1484, 1424, 1346, 1228, 1152, 1147, 1022, 958, 841, 648; ¹H NMR Off-white viscous oil (500 MHz, CDCl₃) δ 7.68 (s, 1H), 7.53 (s, 1H), 7.26 (s, 1H), 5.31 (s, 2H), 4.36 (t, J = 7.2 Hz, 2H), 1.92 (m, 4H), 1.39 (s, 9H), 1.33–1.29 (m, 6H), 0.88 (t, J = 7.4 Hz, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 163.6, 152.9, 152.1, 142.6, 131.4, 125.1, 123.9, 122.9, 113.7, 63.7, 50.6, 33.0, 31.6, 30.21, 28.6, 27.0, 26.4, 22.5, 14.0; HRMS (ESI-TOF) m/z : [M + H]⁺ calcd for C₂₂H₃₀Cl₂N₅O₃ 482.1726; found 482.1728.




5-(*tert*-Butyl)-3-(2,4-dichloro-5-((1-(undec-10-en-1-yl)-1*H*-1,2,3-triazol-4-yl)methoxy)phenyl)-1,3,4-oxadiazol-2(3*H*)-one. Off-white viscous oil (92% yield); IR: (neat) ν (cm⁻¹): 3120, 2984, 1756, 1669, 1651, 1531, 1454, 1345, 1228, 1174, 1012, 1054, 893, 824, 623; ¹H NMR (500 MHz, CDCl₃) δ 7.46 (s, 1H), 7.22 (s, 1H), 5.73 (dt, J = 16.4, 8.0 Hz, 1H), 5.22 (s, 1H), 4.88 (dd, J = 31.3, 13.8 Hz, 2H), 4.81–4.76 (m, 1H), 4.29 (t, J = 7.5 Hz, 1H), 3.18 (m, 3H), 1.96 (q, J = 7.3, 6.7 Hz, 2H), 1.85 (m, 2H), 1.31 (s, 9H), 1.23 (m, 10H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 163.6, 152.9, 152.1, 139.0, 131.3, 131.3, 125.1, 123.8, 114.1, 113.8, 63.5, 50.5, 50.1, 33.7, 30.1, 29.2, 29.0, 28.9, 28.8, 26.9, 26.4; HRMS (ESI-TOF) m/z : [M + H]⁺ calcd for C₂₆H₃₆Cl₂N₅O₃ 536.2195; found 536.2196.




5-(*tert*-Butyl)-3-(2,4-dichloro-5-((1-(4-phenylbutyl)-1*H*-1,2,3-triazol-4-yl)methoxy)phenyl)-1,3,4-oxadiazol-2(3*H*)-one. Off-white viscous oil (96% yield); IR: (neat) ν (cm⁻¹): 3103, 1754, 1623, 1645, 1562, 1482, 1323, 1217, 1123, 1041, 923, 886, 628; ¹H NMR (500 MHz, CDCl₃) δ 7.65 (s, 1H), 7.54 (s, 1H), 7.32–7.28 (m, 3H), 7.27 (s, 1H), 7.21–7.14 (m, 3H), 5.31 (s, 2H), 4.39 (s, 2H), 2.68 (m, 3H), 1.96 (dd, J = 6.2, 2.9 Hz, 1H), 1.69–1.66 (m, 1H), 1.40 (s, 9H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 163.6, 152.9, 152.1, 142.7, 141.4, 131.4, 128.5, 128.4, 126.1, 125.1, 123.9, 123.0, 113.8, 63.7, 50.4, 35.1, 29.7, 28.1, 27.0; HRMS (ESI-TOF) m/z : [M + H]⁺ calcd for C₂₅H₂₈Cl₂N₅O₃ 516.1569; found 516.1568.




**11d**


3-(5-((1-(4-(Benzyloxy)butyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,4-dichlorophenyl)-5-(tert-butyl)-1,3,4-oxadiazol-2(3H)-one. Pale-yellow viscous oil in 90% yield; IR: (neat) ν (cm^{-1}): 2928, 1762, 1661, 1538, 1469, 1438, 1314, 1286, 1118, 1056, 928, 763, 641, 556; ^1H NMR (500 MHz, CDCl_3) δ 7.74–7.66 (s, 1H), 7.63 (s, 1H), 7.50 (s, 1H), 7.35–7.25 (m, 5H), 5.53 (d, J = 6.4 Hz, 2H), 5.29–5.22 (m, 2H), 4.43–4.35 (m, 2H), 3.54–3.47 (m, 2H), 2.04 (dt, J = 14.9, 8.9 Hz, 2H), 1.63 (m, 2H), 1.37 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 163.6, 153.0, 152.9, 152.18, 152.06, 143.0, 142.5, 138.3, 134.4, 131.43, 131.37, 129.1, 128.8, 128.4, 128.1, 127.7, 125.11, 125.09, 123.9, 123.8, 123.19, 123.16, 114.0, 113.8, 73.0, 69.3, 63.7, 54.3, 50.3, 33.0, 27.4, 27.0, 26.6; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{30}\text{Cl}_2\text{N}_5\text{O}_4$ 546.1675; found 546.1678.

**11e**


5-(tert-Butyl)-3-(2,4-dichloro-5-((1-(9-hydroxynonyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1,3,4-oxadiazol-2(3H)-one. Off-white viscous oil (96% yield); IR: (neat) ν (cm^{-1}): 3531, 2935, 1762, 1623, 1523, 1442, 1345, 1231, 1125, 1054, 1023, 956, 862, 674, 586; ^1H NMR (500 MHz, CDCl_3) δ 7.68 (s, 1H), 7.52 (s, 1H), 7.27 (s, 1H), 4.35 (t, J = 7.3 Hz, 2H), 4.11 (q, J = 7.1 Hz, 1H), 3.62 (t, J = 6.6 Hz, 2H), 2.04 (s, 1H), 1.92 (m, 3H), 1.69 (m, 1H), 1.54 (dq, J = 8.0, 6.5 Hz, 2H), 1.37 (s, 9H), 1.32–1.28 (m, 10H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 163.6, 152.9, 152.1, 142.6, 131.4, 125.1, 123.9, 122.9, 113.7, 63.7, 62.9, 50.5, 32.7, 30.2, 29.3, 29.2, 28.8, 27.0, 26.4, 25.6; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{34}\text{Cl}_2\text{N}_5\text{O}_4$ 526.1988; found 526.1986.

**11f**

9-(4-((5-(5-(tert-Butyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2,4-dichlorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)nonyl methanesulfonate. Off-white viscous oil (80% yield); IR: (neat) ν (cm^{-1}): 2995, 1763, 1652, 1609, 1595, 1434, 1328, 1263, 1131, 1047, 968, 847, 723, 668, 547; ^1H NMR (500 MHz, CDCl_3) δ 7.68 (s, 1H), 7.60–7.47 (s, 1H), 7.25 (s, 1H), 5.28 (s, 2H), 4.65–4.58 (m, 1H), 4.32 (t, J = 7.4 Hz, 2H), 4.18 (q, J = 6.5, 5.7 Hz, 1H), 3.53–3.47 (m, 1H), 3.04–2.94 (m, 2H), 2.34 (s, 1H), 2.02 (q, J = 7.6, 7.2 Hz, 1H), 1.91–1.84 (m, 2H), 1.76–1.64 (m, 2H), 1.38 (s, 9H), 1.28 (m, 8H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 152.9, 152.1, 142.5, 131.4, 131.3, 125.0, 123.8, 123.1, 113.8, 70.2, 63.6, 50.5, 37.3, 32.9, 30.13, 30.11, 29.12, 29.05, 29.0, 28.88, 28.75, 28.72, 28.67, 28.65, 26.98, 26.36, 26.31, 25.3; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{36}\text{Cl}_2\text{N}_5\text{O}_6\text{S}$ 604.1763; found 604.1765.

**11g**


9-(4-((5-(5-(tert-Butyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2,4-dichlorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)nonyl pivalate. Off-white viscous oil (90% yield); IR: (neat) ν (cm^{-1}): 3021, 1785, 1728, 1625, 1523, 1485, 1323, 1218, 1173, 1038, 964, 856, 769, 628, 527; ^1H NMR (500 MHz, CDCl_3) δ 7.65 (s, 1H), 7.41 (s, 1H), 7.19 (s, 1H), 5.18 (s, 2H), 4.25 (m, 3H), 3.93 (m, 2H), 3.48 (m, 2H), 3.17 (m, 3H), 1.81 (m, 1H), 1.45 (m, 4H), 1.28 (s, 9H), 1.20 (m, 11H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 178.5, 163.4, 152.9, 152.0, 142.4, 131.4, 131.2, 124.9, 123.6, 123.2, 113.7, 64.3, 63.5, 62.44, 62.40, 51.3, 50.4, 32.6, 29.34, 29.2, 29.0, 28.74, 28.72, 27.1, 26.9, 26.6, 25.7; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{42}\text{Cl}_2\text{N}_5\text{O}_5$ 610.2563; found 610.2565.

**11h**


5-(tert-Butyl)-3-(2,4-dichloro-5-((1-(9-fluorononyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1,3,4-oxadiazol-2(3H)-one. Off-white viscous oil (90% yield); IR: (neat) ν (cm^{-1}): 2892, 1732, 1661, 1645, 1512, 1462, 1317, 1283, 1145, 1032, 1007, 957, 876, 752, 589; ^1H NMR (500 MHz, CDCl_3) δ 7.68 (s, 1H), 7.53 (s, 1H), 7.26 (s, 1H), 5.31 (s, 2H), 4.39–4.35 (m, 2H), 3.53 (t, J = 6.7 Hz, 1H), 1.92 (p, J = 7.6 Hz, 2H), 1.80–1.69 (m, 1H), 1.72–1.59 (m, 1H), 1.42 (d, J = 6.7 Hz, 1H), 1.40 (s, 0H), 1.38 (s, 9H), 1.32 (dt, J = 16.6, 8.4 Hz, 10H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126




MHz, CDCl₃) δ 163.6, 152.9, 152.1, 142.6, 131.4, 125.1, 123.9, 122.9, 113.7, 84.2 (d, J_{C-F} = 164.0 Hz), 63.7, 50.5, 45.1, 33.0, 32.5, 30.2, 29.21, 29.17, 29.15, 28.8, 28.7, 27.0, 26.8, 26.4; ¹⁹F NMR (471 MHz, CDCl₃) δ -218.07; HRMS (ESI-TOF) m/z : [M + H]⁺ calcd for C₂₄H₃₃Cl₂FN₅O₃ 528.1944; found 528.1946.




3-(5-((1-(9-Bromononyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,4-dichlorophenyl)-5-(tert-butyl)-1,3,4-oxadiazol-2(3H)-one. Pale-yellow viscous oil in 98% yield; IR: (neat) ν (cm⁻¹): 2928, 1763, 1612, 1541, 1438, 1341, 1274, 1132, 1074, 941, 832, 686, 528, 567; ¹H NMR (500 MHz, CDCl₃) δ 7.75–7.64 (s, 1H), 7.56–7.48 (s, 1H), 7.32–7.23 (s, 1H), 5.35–5.25 (m, 2H), 4.33 (t, J = 7.5 Hz, 2H), 3.50 (m, 1H), 3.37 (m, 1H), 1.89 (m, 2H), 1.86–1.76 (m, 1H), 1.77–1.68 (m, 1H), 1.39 (m, 2H), 1.36 (s, 9H), 1.33–1.23 (m, 8H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 163.7, 152.9, 152.1, 142.5, 131.42, 131.36, 125.1, 123.8, 123.0, 113.8, 63.7, 50.5, 45.1, 34.0, 32.9, 32.7, 32.5, 30.2, 29.14, 29.11, 28.8, 28.7, 28.5, 28.0, 27.02, 26.99, 26.7, 26.4; HRMS (ESI-TOF) m/z : [M + H]⁺ calcd for C₂₄H₃₃BrCl₂N₅O₃ 588.1144; found 588.1145.




10-(4-((5-(5-(tert-butyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2,4-dichlorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)decanenitrile. Off-white viscous oil (98% yield); IR: (neat) ν (cm⁻¹): 2983, 1747, 1654, 1531, 1495, 1421, 1347, 1204, 1142, 1027, 968, 841, 782, 634, 583; ¹H NMR (500 MHz, CDCl₃) δ 7.73 (s, 1H), 7.55 (s, 1H), 7.26 (s, 1H), 5.32 (s, 2H), 4.37 (m, 2H), 1.92 (t, J = 7.1 Hz, 2H), 1.39 (m, 16H), 1.33 (m, 9H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 163.6, 152.9, 152.1, 131.4, 125.1, 123.9, 113.8, 84.8, 83.5, 63.7, 50.6, 33.0, 30.2, 29.2, 29.1, 28.8, 27.0, 26.4; HRMS (ESI-TOF) m/z : [M + H]⁺ calcd for C₂₅H₃₄Cl₂N₅O₃ 535.1991; found 535.1991.



5-(tert-Butyl)-3-(2,4-dichloro-5-((1-(9-(oxiran-2-yl)nonyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1,3,4-oxadiazol-2(3H)-one. Off-white viscous oil (92% yield); IR: (neat) ν (cm⁻¹): 2972, 1765, 1643, 1547, 1423, 1463, 1375, 1212, 1174, 1047, 962, 868, 684, 556; ¹H NMR (500 MHz, CDCl₃) δ 7.68 (s, 1H), 7.53 (s, 1H), 7.27 (s, 1H), 5.31 (s, 2H), 4.36 (t, J = 7.3 Hz, 2H), 2.90 (m, 1H), 2.74 (dd, J = 5.0, 3.9 Hz, 1H), 2.46 (dd, J = 5.0, 2.7 Hz, 1H), 1.96–1.84 (m, 3H), 1.58–1.50 (m, 1H), 1.53–1.44 (m, 1H), 1.38 (s, 9H), 1.34–1.27 (m, 11H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 163.6, 152.9, 152.1, 142.6, 131.4, 125.1, 123.9, 122.9, 113.7, 63.7, 53.5, 50.5, 47.1, 33.0, 32.5, 30.2, 29.4, 29.3, 29.2, 28.9, 27.0, 26.4, 25.9; HRMS (ESI-TOF) m/z : [M + H]⁺ calcd for C₂₆H₃₇Cl₂N₅O₄ 552.2144; found 552.2146.




5-(tert-Butyl)-3-(2,4-dichloro-5-((1-(10-hydroxy-11-iodoundecyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1,3,4-oxadiazol-2(3H)-one. Pale-yellow viscous oil (78% yield); IR: (neat) ν (cm⁻¹): 3486, 2936, 1762, 1658, 1528, 1453, 1369, 1248, 1136, 1047, 938, 874, 623, 556; ¹H NMR (500 MHz, CDCl₃) δ 7.68 (s, 1H), 7.59–7.49 (s, 1H), 7.32–7.22 (s, 1H), 5.29 (m, 2H), 4.34 (t, J = 6.9 Hz, 2H), 3.53–3.46 (m, 1H), 3.35 (m, 1H), 3.22 (m, 1H), 2.50 (m, 1H), 2.08 (m, 1H), 1.90 (m, 2H), 1.59–1.47 (m, 2H), 1.39–1.36 (s, 9H), 1.30–1.25 (m, 11H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 163.6, 152.9, 152.1, 142.6, 131.40, 131.38, 125.1, 123.8, 123.0, 113.8, 70.8, 63.7, 50.5, 36.5, 33.0, 30.1, 29.3, 29.24, 29.17, 28.8, 27.0, 26.4, 25.6, 16.6; HRMS (ESI-TOF) m/z : [M + H]⁺ calcd for C₂₆H₃₇ICl₂N₅O₄ 680.1267; found 680.1267.




5-(tert-Butyl)-3-(2,4-dichloro-5-((1-(11-fluoro-10-hydroxyundecyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1,3,4-oxadiazol-2(3H)-one. Pale-yellow viscous oil (82% yield); IR: (neat) ν (cm⁻¹): 3428, 2983, 1772, 1698, 1538, 1427, 1386, 1234, 1117, 1066, 958, 829, 667, 568, 538; ¹H NMR (500 MHz, CDCl₃) δ 7.68 (s, 1H), 7.52 (s, 1H), 7.25 (s, 1H), 5.31 (s, 2H), 4.35 (m, 2H), 3.70–3.58 (m, 1H), 3.24 (s, 1H), 1.90 (t, J = 7.3 Hz, 3H), 1.60 (m, 3H), 1.57 (m, 1H), 1.37 (s, 9H), 1.26 (m, 11H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 163.6, 152.9, 152.1, 142.6, 131.4, 125.1, 123.9, 122.99, 122.97, 113.7, 71.8 (d, J_{C-F} = 107.3 Hz), 66.9, 63.7, 50.5, 34.2, 33.2, 33.1, 33.0, 30.1, 29.6, 29.5,




29.4, 29.2, 29.2, 29.0, 28.80, 28.77, 27.0, 26.7; HRMS (ESI-TOF) m/z : $[M + H]^+$ Calcd for $C_{26}H_{37}Cl_2FN_5O_4$ 572.2207; found 572.2209.




5-(tert-butyl)-3-(5-((1-(11-(tert-butylamino)-10-hydroxyundecyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,4-dichlorophenyl)-1,3,4-oxadiazol-2(3H)-one. Pale-yellow viscous oil (88% yield); IR: (neat) ν (cm^{-1}): 3486, 3286, 2918, 1763, 1638, 1541, 1463, 1417, 1338, 1239, 1129, 1068, 972, 823, 659, 538, 528; 1H NMR (500 MHz, $CDCl_3$) δ 7.68 (s, 1H), 7.49 (s, 1H), 7.25 (s, 1H), 5.29 (s, 2H), 4.32 (m, 3H), 4.07 (m, 2H), 3.23 (m, 1H), 2.98 (m, 2H), 2.77 (m, 1H), 1.88 (m, 3H), 1.57 (m, 2H), 1.46–1.34 (s, 9H), 1.33–1.17 (m, 18H); $^{13}C\{^1H\}$ NMR (126 MHz, $CDCl_3$) δ 163.6, 153.0, 152.1, 142.5, 131.4, 131.3, 125.0, 123.8, 123.0, 113.7, 66.8, 63.7, 57.2, 51.4, 50.5, 48.4, 34.8, 32.9, 30.2, 29.44, 29.37, 29.30, 29.2, 28.9, 27.0, 26.4, 25.9, 25.4; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{30}H_{47}Cl_2N_6O_4$ 625.3036; found 625.3037.




3-(5-((1-(11-Amino-10-hydroxyundecyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,4-dichlorophenyl)-5-(tert-butyl)-1,3,4-oxadiazol-2(3H)-one. See SI for synthesis. Pale-yellow viscous oil (86% yield); IR: (neat) ν (cm^{-1}): 3562, 3452, 2989, 1763, 1638, 1563, 1428, 1439, 1374, 1269, 1132, 1068, 939, 738, 647, 547; 1H NMR (500 MHz, $CDCl_3$) δ 7.75 (s, 1H), 7.51 (s, 1H), 7.28 (s, 1H), 5.27 (s, 2H), 4.33 (m, 2H), 3.96–3.93 (m, 3H), 3.11 (m, 2H), 2.95 (m, 2H), 1.89 (m, 3H), 1.36 (s, 9H), 1.24 (m, 10H); $^{13}C\{^1H\}$ NMR (126 MHz, $CDCl_3$) δ 163.6, 152.9, 152.2, 142.5, 131.43, 131.36, 125.0, 123.9, 123.3, 113.8, 68.0, 63.6, 50.5, 45.4, 34.9, 33.0, 30.2, 29.5, 29.40, 29.35, 28.9, 27.03, 27.01, 26.4, 25.4; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{26}H_{39}Cl_2N_6O_4$ 569.2410; found 569.2412.



5-(tert-butyl)-3-(2,4-dichloro-5-((1-(10-hydroxy-11-(phenethylamino)undecyl)-1H-1,2,3-triazol-4-yl)methoxy)-phenyl)-1,3,4-oxadiazol-2(3H)-one. Pale-yellow viscous oil (92% yield); IR: (neat) ν (cm^{-1}): 3486, 3304, 2962, 1736, 1642, 1528, 1414, 1401, 1328, 1236, 1169, 1042, 986, 725, 638, 589, 528; 1H NMR (500 MHz, $CDCl_3$) δ 7.84 (s, 1H), 7.69 (s, 1H), 7.49 (s, 1H), 7.28 (s, 3H), 7.21–7.18 (m, 2H), 5.28 (s, 2H), 4.36–4.27 (m, 2H), 3.20 (m, 1H), 2.91 (m, 2H), 2.87–2.77 (m, 1H), 1.91–1.83 (m, 2H), 1.45 (m, 2H), 1.37 (m, 12H), 1.26 (m, 11H); $^{13}C\{^1H\}$ NMR (126 MHz, $CDCl_3$) δ 163.6, 152.9, 152.1, 142.5, 131.42, 131.35, 128.8, 128.73, 128.71, 128.6, 125.1, 123.8, 123.1, 113.8, 63.6, 53.5, 50.5, 32.9, 30.2, 29.3, 29.2, 28.8, 27.0, 26.4; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{34}H_{47}Cl_2N_6O_4$ 673.3036; found 673.3035.




3-(5-((1-(11-(Benzhydrylamino)-10-hydroxyundecyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,4-dichlorophenyl)-5-(tert-butyl)-1,3,4-oxadiazol-2(3H)-one. Pale-yellow viscous oil (90% yield); IR: (neat) ν (cm^{-1}): 3521, 3289, 2982, 1742, 1632, 1587, 1458, 1456, 1363, 1225, 1174, 1023, 953, 848, 732, 678, 556; 1H NMR (500 MHz, $CDCl_3$) δ 7.67 (s, 1H), 7.57–7.51 (s, 1H), 7.43–7.34 (m, 4H), 7.33–7.19 (m, 6H), 5.29 (s, 2H), 4.84 (m, 1H), 4.33 (t, $J = 7.3$ Hz, 2H), 3.64 (m, 1H), 2.71 (m, 2H), 2.70 (m, 1H), 2.49–2.43 (m, 1H), 1.90 (m, 2H), 1.38 (m, 9H), 1.33–1.23 (m, 13H); $^{13}C\{^1H\}$ NMR (126 MHz, $CDCl_3$) δ 163.6, 153.0, 152.1, 143.7, 143.4, 142.5, 131.4, 128.5, 127.3, 127.22, 127.15, 123.0, 113.8, 70.2, 67.2, 63.7, 53.7, 50.5, 35.0, 33.0, 30.2, 29.6, 29.4, 29.3, 28.9, 27.0, 26.4, 25.6; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{39}H_{49}Cl_2N_6O_4$ 735.3192; found 735.3194.




Diethyl(3-(4-((5-(5-(tert-butyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2,4-dichlorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)-phosphonate. Off-white viscous oil (85% yield); IR: (neat) ν (cm^{-1}): 2923, 1765, 1625, 1586, 1524, 1468, 1345, 1282, 1204, 1156, 923, 865, 745, 571; 1H NMR (500 MHz, $CDCl_3$) δ 7.76 (s, 1H), 7.51 (s, 1H), 7.26–7.22 (s, 1H), 5.29 (s, 2H), 4.48 (m, 2H), 4.09–4.07 (m, 2H), 2.23 (s, 1H), 1.74–1.69 (m, 2H), 1.44–1.34 (s, 9H), 1.34–1.26 (m, 9H); $^{13}C\{^1H\}$ NMR (126 MHz, $CDCl_3$) δ 163.6, 152.9, 152.1, 142.7, 131.41, 131.38, 125.1, 123.9, 123.5, 113.7, 63.6, 61.9, 61.8, 50.2, 50.0, 32.9, 27.0, 23.6, 23.6, 23.0, 21.9, 16.5, 16.4; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{22}H_{31}Cl_2N_5O_6P$ 562.1389; found 562.1387.







Diethyl(4-(4-((5-(5-(*tert*-butyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2,4-dichlorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)butyl)phosphonate. Off-white viscous oil (90% yield); IR: (neat) ν (cm^{-1}): 2962, 1753, 1645, 1634, 1547, 1431, 1367, 1238, 1128, 1063, 975, 852, 762, 612, 537; ^1H NMR (500 MHz, CDCl_3) δ 7.69 (s, 1H), 7.48 (s, 1H), 7.22 (s, 1H), 5.26 (s, 2H), 4.36 (m, 2H), 4.06–3.98 (m, 2H), 2.70 (m, 1H), 2.66 (s, 9H), 2.43 (m, 11H), 1.33 (t, $J = 7.4$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 163.6, 152.9, 152.1, 142.6, 131.4, 125.1, 123.8, 123.2, 113.7, 63.5, 61.63, 61.58, 49.8, 32.9, 30.7, 30.6, 27.0, 25.4, 24.3, 19.62, 19.58, 16.44, 16.39; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{323}\text{Cl}_2\text{N}_5\text{O}_6\text{P}$ 576.1546; found 576.1546.




Diethyl(5-(4-((5-(5-(*tert*-butyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2,4-dichlorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)pentyl)phosphonate. Off-white viscous oil (88% yield); IR: (neat) ν (cm^{-1}): 2982, 1745, 1636, 1621, 1536, 1458, 1339, 1221, 1172, 1028, 968, 823, 712, 543; ^1H NMR (500 MHz, CDCl_3) δ 7.68 (s, 1H), 7.54–7.48 (s, 1H), 7.32–7.21 (s, 1H), 5.28 (s, 2H), 4.41–4.31 (m, 2H), 4.13–4.04 (m, 2H), 4.08–3.99 (m, 2H), 1.99–1.88 (m, 2H), 1.76–1.58 (m, 4H), 1.48–1.35 (m, 1H), 1.40–1.33 (s, 9H), 1.34–1.21 (m, 7H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 163.6, 152.9, 152.1, 142.6, 131.4, 125.1, 123.9, 123.0, 113.7, 63.6, 61.54, 61.49, 50.2, 32.9, 29.8, 27.3, 27.2, 27.0, 25.9, 24.8, 22.0, 21.9, 16.5, 16.4; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{35}\text{Cl}_2\text{N}_5\text{O}_6\text{P}$ 590.1702; found 590.1704.



(3-(4-((5-(5-(*tert*-Butyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2,4-dichlorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)phosphonic acid. See SI for synthesis. Pale-yellow viscous oil (68% yield); IR: (neat) ν (cm^{-1}): 2982, 1763, 1672, 1617, 1568, 1439, 1364, 1233, 1127, 1051, 928, 874, 741, 653, 528; ^1H NMR (500 MHz, CD_3OD) δ 8.27 (s, 1H), 7.67 (s, 1H), 7.65 (s, 1H), 5.33 (s, 2H), 4.57 (m, 2H), 2.11 (m, 3H), 1.84 (m, 3H), 1.40 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CD_3OD) δ 163.5, 153.1, 152.5, 131.6, 130.7, 125.0, 124.9, 123.5, 114.5, 62.6, 32.6, 26.0; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{23}\text{Cl}_2\text{N}_5\text{O}_6\text{P}$ 506.0763; found 506.0765.



(4-(4-((5-(5-(*tert*-Butyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2,4-dichlorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)butyl)phosphonic acid. See SI for synthesis. Prepared using the procedure outlined for 19n. pale-yellow viscous oil (74% yield); IR: (neat) ν (cm^{-1}): 2986, 1772, 1663, 1598, 1523, 1434, 1341, 1232, 1124, 1036, 928, 821, 753, 674, 521; ^1H NMR (500 MHz, CD_3OD) δ 8.24 (s, 1H), 7.68 (s, 1H), 7.63 (s, 1H), 5.32 (s, 2H), 4.49 (t, $J = 6.9$ Hz, 2H), 2.04 (m, 3H), 1.65 (m, 6H), 1.40 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CD_3OD) δ 163.5, 153.1, 152.5, 142.1, 131.6, 130.7, 124.9, 124.8, 123.7, 114.4, 62.6, 49.9, 32.6, 26.0; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{25}\text{Cl}_2\text{N}_5\text{O}_6\text{P}$ 519.0841; found 519.0845.



Conflicts of interest

There is no conflict of interest to declare.

Data availability

The data supporting this article have been included as part of the supplementary information (SI). Supplementary information is available. See DOI: <https://doi.org/10.1039/d5md00888c>.



Acknowledgements

D. C. W.'s lab was partially supported by a grant from NIH NIGMS (R35GM153221) and a RPL project associated with a Phase II COBRE Center (P20GM146584). Z. D.'s laboratory was supported by NIH R01AI143707 to this work. The authors are grateful to Prof. R. Adam Mosey (Lake Superior State University) for HRMS analysis.

References

- 1 M. W. Black and J. C. Boothroyd, Lytic Cycle of *Toxoplasma gondii*, *Microbiol. Mol. Biol. Rev.*, 2000, **64**, 607–623.
- 2 S. O. Angel, L. Vanagas, D. M. Ruiz, C. Cristaldi, A. M. Saldarriaga Cartagena and W. J. Sullivan, Emerging Therapeutic Targets Against *Toxoplasma gondii*: Update on DNA Repair Response Inhibitors and Genotoxic Drugs, *Front. Cell. Infect. Microbiol.*, 2020, **10**, 289.
- 3 A. M. Tenter, A. R. Heckeroth and L. M. Weiss, *Toxoplasma gondii*: From Animals to Humans, *Int. J. Parasitol.*, 2000, **30**, 1217–1258.
- 4 S. K. Halonen and L. M. Weiss, Toxoplasmosis, *Handb. Clin. Neurol.*, 2013, **114**, 125145.
- 5 H. Safarpour, M. Cevik, M. Zarean, A. Barac, K. Hatam-Nahavandi, M. T. Rahimi, H. Bannazadeh Baghi, T. J. Koshki, A. S. Pagheh, F. Shahriver, M. Ebrahimi and E. Ahmadpour, Global Status of *Toxoplasma gondii* Infection and Associated Risk Factors in People Living with HIV, *Aids*, 2020, **34**(3), 469–474.
- 6 Z. D. Wang, S. C. Wang, H. H. Liu, H. Y. Ma, Z. Y. Li, F. Wei, X. Q. Zhu and Q. Liu, Prevalence and Burden of *Toxoplasma gondii* Infection in HIV-Infected People: A Systematic Review and Meta-Analysis, *Lancet HIV*, 2017, **4**(4), e177–e188.
- 7 V. O. Martinez, F. W. de Mendonça Lima, C. F. de Carvalho and J. A. Menezes-Filho, *Toxoplasma gondii* Infection and Behavioral Outcomes in Humans: A Systematic Review, *Parasitol. Res.*, 2018, **117**(10), 3059–3065.
- 8 T. Nayeri Chegeni, S. Sarvi, M. Moosazadeh, M. Sharif, S. A. Aghayan, A. Amouei, Z. Hosseinienejad and A. Daryani, Is *Toxoplasma gondii* a Potential Risk Factor for Alzheimer's Disease? A Systematic Review and Meta-Analysis, *Microb. Pathog.*, 2019, **137**, 103751.
- 9 M. Bayani, S. M. Riahi, N. Bazrafshan, H. Ray Gamble and A. Rostami, *Toxoplasma gondii* Infection and Risk of Parkinson and Alzheimer Diseases: A Systematic Review and Meta-Analysis on Observational Studies, *Acta Trop.*, 2019, **196**, 165–171.
- 10 J. Flegr and A. Markoš, Masterpiece of Epigenetic Engineering - How *Toxoplasma gondii* reprogrammes Host Brains to Change Fear to Sexual Attraction, *Mol. Ecol.*, 2014, **23**(24), 5934–5936.
- 11 Z. D. Wang, H. H. Liu, Z. X. Ma, H. Y. Ma, Z. Y. Li, Z. Bin Yang, X. Q. Zhu, B. Xu, F. Wei and Q. Liu, *Toxoplasma gondii* Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis, *Front. Microbiol.*, 2017, **8**, 389.
- 12 D. Anvari, M. Sharif, S. Sarvi, S. A. Aghayan, S. Gholami, A. S. Pagheh, S. A. Hosseini, R. Saberi, T. N. Chegeni, Z. Hosseinienejad and A. Daryani, Seroprevalence of *Toxoplasma gondii* Infection in Cancer Patients: A Systematic Review and Meta-Analysis, *Microb. Pathog.*, 2019, **129**, 30–42.
- 13 M. Montazeri, S. Mehrzadi, M. Sharif, S. Sarvi, A. Tanzifi, S. A. Aghayan and A. Daryani, Drug Resistance in *Toxoplasma gondii*, *Front. Microbiol.*, 2018, **9**, 2587.
- 14 S. M. Sidik, D. Huet, S. M. Ganesan, M. Huynh, T. Wang, A. S. Nasamu, P. Thiru, J. P. J. Saeij, V. B. Carruthers, J. C. Niles and S. Lourido, A Genome-Wide 401CRISPR Screen in *Toxoplasma* Identifies Essential Apicomplexan Genes, *Cell*, 2016, **167**(6), 1423–1430.
- 15 L. Kořený, M. Oborník and J. Lukeš, Make It, Take It, or Leave It: Heme Metabolism of Parasites, *PLoS Pathog.*, 2013, **9**, e1003088.
- 16 A. Bergmann, K. Floyd, M. Key, C. Dameron, K. C. Rees, L. B. Thornton, D. C. Whitehead, I. Hamza and Z. Dou, *Toxoplasma gondii* Requires Its Plant-Like Heme Biosynthesis Pathway for Infection, *PLoS Pathog.*, 2020, **16**, e1008499.
- 17 M. Key, A. Bergmann, C. Micchelli, L. B. Thornton, S. Millard and Z. Dou, Determination of Chemical Inhibitor Efficiency against Intracellular *Toxoplasma gondii* Growth Using a Luciferase-Based Growth Assay, *J. Visualized Exp.*, 2020, **158**, e60985.
- 18 G.-F. Hao, Y. Zuo, S.-G. Yang and G.-F. Yang, Protoporphyrinogen oxidase inhibitor: an ideal target for herbicide discovery, *Chimia*, 2011, **65**, 961–969.
- 19 K. C. Rees, Z. Dou and D. C. Whitehead, Oxadiazon Derivatives Elicit Potent Intracellular Growth Inhibition against *Toxoplasma gondii* by Disrupting Heme Biosynthesis, *ACS Infect. Dis.*, 2022, **8**, 911–917.
- 20 A. Bergman and Z. Dou, Fluorescence-based Heme Quantification in *Toxoplasma gondii*, *Bio-Protoc.*, 2021, **11**, e4063.
- 21 A. E. Maclean, H. R. Bridges, M. F. Silva, S. Ding, J. Ovicarikova, J. Hirst and L. Sheiner, Complexome profile of *Toxoplasma gondii* mitochondria identifies divergent subunits of respiratory chain complexes including new subunits of cytochrome bc1 complex, *PLoS Pathog.*, 2021, **17**, e1009301.
- 22 J. A. Hayward, E. Rajendran, F. V. Makota, B. J. Bassett, M. Devoy, T. Neeman and G. G. van Dooren, Real-Time Analysis of Mitochondrial Electron Transport Chain Function in *Toxoplasma gondii* Parasites Using a Seahorse XFe96 Extracellular Flux Analyzer, *Bio-Protoc.*, 2022, **5**, e4288.

